Top

Published in:

Open Access 01-02-2011 | Original

Rizatriptan reduces vestibular-induced motion sickness in migraineurs

Authors: Joseph M. Furman, Dawn A. Marcus, Carey D. Balaban

Published in: The Journal of Headache and Pain | Issue 1/2011

Abstract

A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo. Subjects included 25 migraineurs with or without migraine-related dizziness (23 females) aged 21–45 years (31.0 ± 7.8 years). Motion sickness was induced by off-vertical axis rotation in darkness, which stimulates both the semicircular canals and otolith organs of the vestibular apparatus. Results indicated that of the 15 subjects who experienced vestibular-induced motion sickness when pretreated with placebo, 13 showed a decrease in motion sickness following pretreatment with rizatriptan as compared to pretreatment with placebo (P < 0.02). This significant effect was not seen when subjects were exposed to more provocative vestibular stimulation. We conclude that the serotonin agonist, rizatriptan, reduces vestibular-induced motion sickness by influencing serotonergic vestibular-autonomic projections.

Irwin JA (1881) The pathology of sea-sickness. Lancet 2:907–909, 10.1016/S0140-6736(02)38129-7CrossRef

Marcus DA, Furman JM, Balaban CD (2005) Motion sickness in migraine sufferers. Expert Opin Pharmacother 6(15):2691–2697, 16316307, 10.1517/14656566.6.15.2691, 1:CAS:528:DC%2BD2MXht1Gks73KCrossRefPubMed

Graybiel A, Wood CD, Miller EF, Cramer DB (1968) Diagnostic criteria for grading the severity of acute motion sickness. Aerosp Med 39(5):453–455, 5648730, 1:STN:280:DyaF1c3jsFymsg%3D%3DPubMed

Kayan A, Hood JD (1984) Neuro-otological manifestations of migraine. Brain 107(Pt 4):1123–1142, 6334543, 10.1093/brain/107.4.1123CrossRefPubMed

Drummond PD (2005) Triggers of motion sickness in migraine sufferers. Headache 45(6):653–656, 15953297, 10.1111/j.1526-4610.2005.05132.xCrossRefPubMed

Turner M, Griffin MJ, Holland I (2000) Airsickness and aircraft motion during short-haul flights. Aviat Space Environ Med 71(12):1181–1189, 11439716, 1:STN:280:DC%2BD3Mzos1CjtA%3D%3DPubMed

Yates BJ, Miller AD, Lucot JB (1998) Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull 47(5):395–406, 10052567, 10.1016/S0361-9230(98)00092-6, 1:STN:280:DyaK1M7lvF2gsA%3D%3DCrossRefPubMed

Takeda N, Morita M, Horii A, Nishiike S, Kitahara T, Uno A (2001) Neural mechanisms of motion sickness. J Med Invest 48(1–2):44–59, 11286016, 1:STN:280:DC%2BD3Mzgs1KrsA%3D%3DPubMed

Javid FA, Naylor RJ (2002) The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav 73(4):979–989, 12213545, 10.1016/S0091-3057(02)00955-3, 1:CAS:528:DC%2BD38Xms1yltrg%3DCrossRefPubMed

10.

Furman JM, Marcus DA (2009) A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. Int J Med Sci 6(4):212–217, 19680473, 1:CAS:528:DC%2BD1MXhtVSksL%2FEPubMedCentralCrossRefPubMed

11.

Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T (2001) The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 56(4):436–441

12.

Abu-Arafeh I, Russell G. Paroxysmal vertigo as a migraine equivalent in children: a population-based study. Cephalalgia 15(1):22–5 (discussion 4)

13.

The International Classification of Headache Disorders (2004) 2nd edn. Cephalalgia 24(Suppl 1):9–160

14.

Marcus DA, Kapelewski C, Rudy TE, Jacob JG, Furman JM (2004) Diagnosis of migrainous vertigo: validity of a structured interview. Med Sci Monit 10(5):CR197–201

15.

Marcus DA, Kapelewski C, Jacob RG, Rudy TE, Furman JM (2004) Validation of a brief nurse-administered migraine assessment tool. Headache 44(4):328–332, 15109357, 10.1111/j.1526-4610.2004.04076.xCrossRefPubMed

16.

Furman JM, Wuyts F (2003) Vestibular test techniques. In: Luxon LM, Martini A, Furman JM, Stephens D (eds) Textbook of audiological medicine. Martin Dunitz, London, pp 735–746

17.

Wolpe J (1982) The practice of behavior therapy. Pergamon Press, New York

18.

Furman JM, Schor RH, Schumann TL (1992) Off-vertical axis rotation: a test of the otolith-ocular reflex. Ann Otol Rhinol Laryngol 101(8):643–650, 1497268, 1:STN:280:DyaK38zlvFCgug%3D%3DCrossRefPubMed

19.

Denise P, Etard O, Zupan L, Darlot C (1996) Motion sickness during off-vertical axis rotation: prediction by a model of sensory interactions and correlation with other forms of motion sickness. Neurosci Lett 203(3):183–186, 8742023, 10.1016/0304-3940(96)12303-X, 1:CAS:528:DyaK28XhtVWis7k%3DCrossRefPubMed

20.

Marcus DA, Furman JM (2006) Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit 12(1):PI1–7

21.

Evans RW, Marcus D, Furman JM (2007) Motion sickness and migraine. Headache 47(4):607–610, 17445111, 10.1111/j.1526-4610.2007.00762.xCrossRefPubMed

22.

Neuhauser HK, Radtke A, von Brevern M, Feldmann M, Lezius F, Ziese T et al (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67(6):1028–1033, 17000973, 10.1212/01.wnl.0000237539.09942.06, 1:STN:280:DC%2BD28rnt1Shug%3D%3DCrossRefPubMed

23.

Jeong SH, Oh SY, Kim HJ, Koo JW, Kim JS (2009) Vestibular dysfunction in migraine: effects of associated vertigo and motion sickness. J Neurol 257(6):905–912, 20041331, 10.1007/s00415-009-5435-5CrossRefPubMed

24.

Ahn S-K, Balaban CD (2010) Distribution of 5-HT1B and 5-HT1D receptors in the inner ear. Brain Res 1346:92–101

25.

Kitahara T, Li HS, Balaban CD (2005) Changes in transient receptor potential cation channel superfamily V (TRPV) mRNA expression in the mouse inner ear ganglia after kanamycin challenge. Hear Res 201(1–2):132–144, 15721568, 10.1016/j.heares.2004.09.007, 1:CAS:528:DC%2BD2MXhsVOntrk%3DCrossRefPubMed

26.

Kevetter GA, Leonard RB (2002) Molecular probes of the vestibular nerve. II. Characterization of neurons in Scarpa’s ganglion to determine separate populations within the nerve. Brain Res 928(1–2):18–29, 11844468, 10.1016/S0006-8993(01)03264-4, 1:CAS:528:DC%2BD38Xht1ahs70%3DCrossRefPubMed

27.

Xiang Z, Bo X, Burnstock G (1999) P2X receptor immunoreactivity in the rat cochlea, vestibular ganglion and cochlear nucleus. Hear Res 128(1–2):190–196, 10082298, 10.1016/S0378-5955(98)00208-1, 1:CAS:528:DyaK1MXhs1Cmtrw%3DCrossRefPubMed

28.

Koo JW, Balaban CD (2006) Serotonin-induced plasma extravasation in the murine inner ear: possible mechanism of migraine-associated inner ear dysfunction. Cephalalgia 26(11):1310–1319, 17059438, 10.1111/j.1468-2982.2006.01208.xCrossRefPubMed

29.

Afridi SK, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RS et al (2005) A positron emission tomographic study in spontaneous migraine. Arch Neurol 62(8):1270–1275, 16087768, 10.1001/archneur.62.8.1270CrossRefPubMed

30.

Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RS et al (2005) A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128(Pt 4):932–939, 15705611, 10.1093/brain/awh416, 1:STN:280:DC%2BD2M7lsV2jug%3D%3DCrossRefPubMed

31.

Afridi SK, Goadsby PJ (2006) Neuroimaging of migraine. Curr Pain Headache Rep 10(3):221–224, 18778577, 10.1007/s11916-006-0049-4CrossRefPubMed

32.

May A, Matharu M (2007) New insights into migraine: application of functional and structural imaging. Curr Opin Neurol 20(3):306–309, 17495625, 10.1097/WCO.0b013e328136c20bCrossRefPubMed

33.

May A (2006) A review of diagnostic and functional imaging in headache. J Headache Pain 7(4):174–184, 16897620, 10.1007/s10194-006-0307-1PubMedCentralCrossRefPubMed

34.

Graybiel A, Knepton J (1976) Sopite syndrome: a sometimes sole manifestation of motion sickness. Aviat Space Environ Med 47(8):873–882, 949309, 1:STN:280:DyaE283lt1eltw%3D%3DPubMed

35.

Bernard JF, Bandler R (1998) Parallel circuits for emotional coping behaviour: new pieces in the puzzle. J Comp Neurol 401(4):429–436, 9826271, 10.1002/(SICI)1096-9861(19981130)401:4<429::AID-CNE1>3.0.CO;2-3, 1:STN:280:DyaK1M%2FktFKntg%3D%3DCrossRefPubMed

36.

Bandler R, Price JL, Keay KA (2000) Brain mediation of active and passive emotional coping. Prog Brain Res (122):331–349

37.

Donaldson C, Boers PM, Hoskin KL, Zagami AS, Lambert GA (2002) The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology 42(3):374–385, 11897116, 10.1016/S0028-3908(01)00190-3, 1:CAS:528:DC%2BD38XhvVCjsL8%3DCrossRefPubMed

38.

Goadsby PJ, Classey JD (2003) Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122(2):491–498, 14614913, 10.1016/S0306-4522(03)00570-0, 1:CAS:528:DC%2BD3sXovVWhu74%3DCrossRefPubMed

39.

Jeggo RD, Wang Y, Jordan D, Ramage AG (2007) Activation of 5-HT1B and 5-HT1D receptors in the rat nucleus tractus solitarius: opposing action on neurones that receive an excitatory vagal C-fibre afferent input. Br J Pharmacol 150(8):987–995, 17339842, 10.1038/sj.bjp.0707169, 1:CAS:528:DC%2BD2sXkt1Chsrs%3DPubMedCentralCrossRefPubMed

40.

Jennings EA, Ryan RM, Christie MJ (2004) Effects of sumatriptan on rat medullary dorsal horn neurons. Pain 111:30–37, 15327806, 10.1016/j.pain.2004.05.018, 1:CAS:528:DC%2BD2cXmvFWrur4%3DCrossRefPubMed

41.

Matsuoka T, Hasuo H, Akasu T (2004) 5-Hydroxytryptamine 1B receptors mediate presynaptic inhibition of monosynaptic IPSC in the rat dorsolateral septal nucleus. Neurosci Res 48(3):229–238, 15154669, 10.1016/j.neures.2003.11.004, 1:CAS:528:DC%2BD2cXhtFCitL0%3DCrossRefPubMed

42.

Bartsch T, Knight YE, Goadsby PJ (2004) Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 56(3):371–381, 15349864, 10.1002/ana.20193, 1:CAS:528:DC%2BD2cXotFyhs70%3DCrossRefPubMed

43.

Ahn S-K, Balaban CD (2007) Regional distribution of 5-HT1A, 1B, and 1D receptors in rat vestibular nuclei (VN). Soc Neurosci Abstr 37(#180.5)

44.

Dai M, Raphan T, Cohen B (2007) Labyrinthine lesions and motion sickness susceptibility. Exp Brain Res 178(4):477–487, 17256169, 10.1007/s00221-006-0759-1PubMedCentralCrossRefPubMed

Title: Rizatriptan reduces vestibular-induced motion sickness in migraineurs
Authors: Joseph M. Furman
Dawn A. Marcus
Carey D. Balaban
Publication date: 01-02-2011
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2011
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1007/s10194-010-0250-z

At a glance: The STEP trials

Springer Medicine

Rizatriptan reduces vestibular-induced motion sickness in migraineurs

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Why pharmacokinetic differences among oral triptans have little clinical importance: a comment

Cortical-spreading depression: at the razor’s edge of scientific logic

What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information?

Overview of diagnosis and management of paediatric headache. Part II: therapeutic management

Alexithymia in juvenile primary headache sufferers: a pilot study

Migraine and sleep apnea in the general population